GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celldex Therapeutics Inc (STU:TCE2) » Definitions » Cyclically Adjusted Revenue per Share

Celldex Therapeutics (STU:TCE2) Cyclically Adjusted Revenue per Share : €0.65 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Celldex Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Celldex Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was €0.002. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.65 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Celldex Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -2.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -20.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -35.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -27.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Celldex Therapeutics was 2.30% per year. The lowest was -41.70% per year. And the median was -15.60% per year.

As of today (2024-05-28), Celldex Therapeutics's current stock price is €33.80. Celldex Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €0.65. Celldex Therapeutics's Cyclically Adjusted PS Ratio of today is 52.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Celldex Therapeutics was 73.07. The lowest was 0.39. And the median was 19.01.


Celldex Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Celldex Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celldex Therapeutics Cyclically Adjusted Revenue per Share Chart

Celldex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 1.12 0.96 0.73 0.64

Celldex Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.68 0.69 0.64 0.65

Competitive Comparison of Celldex Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PS Ratio falls into.



Celldex Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celldex Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.002/131.7762*131.7762
=0.002

Current CPI (Mar. 2024) = 131.7762.

Celldex Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.073 100.560 0.096
201409 0.143 100.428 0.188
201412 0.201 99.070 0.267
201503 0.073 99.621 0.097
201506 0.296 100.684 0.387
201509 0.139 100.392 0.182
201512 0.250 99.792 0.330
201603 0.178 100.470 0.233
201606 0.188 101.688 0.244
201609 0.295 101.861 0.382
201612 0.247 101.863 0.320
201703 0.175 102.862 0.224
201706 0.408 103.349 0.520
201709 0.381 104.136 0.482
201712 0.321 104.011 0.407
201803 0.352 105.290 0.441
201806 0.241 106.317 0.299
201809 0.074 106.507 0.092
201812 0.133 105.998 0.165
201903 0.103 107.251 0.127
201906 0.045 108.070 0.055
201909 0.032 108.329 0.039
201912 0.048 108.420 0.058
202003 0.142 108.902 0.172
202006 0.010 108.767 0.012
202009 0.014 109.815 0.017
202012 0.078 109.897 0.094
202103 0.015 111.754 0.018
202106 0.073 114.631 0.084
202109 0.003 115.734 0.003
202112 0.006 117.630 0.007
202203 0.003 121.301 0.003
202206 0.003 125.017 0.003
202209 0.009 125.227 0.009
202212 0.032 125.222 0.034
202303 0.019 127.348 0.020
202306 0.005 128.729 0.005
202309 0.030 129.860 0.030
202312 0.073 129.419 0.074
202403 0.002 131.776 0.002

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Celldex Therapeutics  (STU:TCE2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Celldex Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=33.80/0.65
=52.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Celldex Therapeutics was 73.07. The lowest was 0.39. And the median was 19.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Celldex Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Celldex Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Celldex Therapeutics (STU:TCE2) Business Description

Industry
Traded in Other Exchanges
Address
53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.

Celldex Therapeutics (STU:TCE2) Headlines

No Headlines